Protalix BioTherapeutics, Inc. (PLX) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-03-18
How it makes money
It earns by manufacturing and selling enzymes to pharmaceutical partners, who then handle end-user distribution and generate final patient revenue.
The company produces enzyme replacement therapies using a proprietary plant cell-based expression system. It sells these finished drug substances in bulk to partners like Pfizer and Chiesi, who manage the global marketing and patient sales. Consequently, the company's revenue is driven by the volume and timing of these wholesale orders rather than direct patient demand.
What protects it: the moat
Management claims its proprietary plant cell-based protein expression system creates a unique method for industrial-scale manufacturing that competitors cannot easily replicate.
The company asserts that its ProCellEx platform, which uses plant cells in suspension to create recombinant proteins, is the first and only system of its kind with FDA approval. This specialized infrastructure is presented as a structural barrier to entry for other developers of enzyme replacement therapies.
What growth costs
Growth requires significant, ongoing investment in expensive and unpredictable clinical trials to validate new drug candidates before commercialization can begin.
Because it operates as a biopharmaceutical company, its primary growth cost is the R&D expenditure required to advance candidates like PRX-115 through Phase 2 trials and beyond. These activities are characterized as difficult to design, time-consuming, and prone to unforeseen costs.
What could damage it
Manufacturing disruptions at its facilities or those of its third-party providers would prevent it from supplying partners, instantly halting its primary revenue stream.
Since the company depends on high-volume, wholesale drug substance sales to a very small number of partners, any technical or regulatory failure that prevents consistent production would immediately result in the cessation of orders, as it lacks diversified revenue sources or a direct-to-patient retail infrastructure.
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.